Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials
Authors
Keywords
Adverse events, Cardiovascular diseases, Blood pressure, Forecasting, Cholesterol, Drug therapy, Creatinine, Statins
Journal
PLOS MEDICINE
Volume 14, Issue 10, Pages e1002410
Publisher
Public Library of Science (PLoS)
Online
2017-10-18
DOI
10.1371/journal.pmed.1002410
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hypertension in 2017—What Is the Right Target?
- (2017) Aram V. Chobanian JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015
- (2017) Mohammad H. Forouzanfar et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients
- (2017) Chirag Bavishi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Personalizing the Intensity of Blood Pressure Control
- (2017) Krishna K. Patel et al. Circulation-Cardiovascular Quality and Outcomes
- Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT)
- (2017) Rajiv Agarwal Journal of the American Heart Association
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention
- (2016) Robert W. Yeh et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
- (2016) Xinfang Xie et al. LANCET
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement
- (2015) Gary S Collins et al. BMC Medicine
- Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition
- (2015) Christopher J L Murray et al. LANCET
- Redefining Blood-Pressure Targets — SPRINT Starts the Marathon
- (2015) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
- (2015) Noah Simon et al. Journal of Statistical Software
- Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials
- (2014) J. F. Burke et al.
- Blood pressure lowering and cardiovascular risk – Authors' reply
- (2014) Johan Sundström et al. LANCET
- Interpretation of Subgroup Analyses in Randomized Trials: Heterogeneity Versus Secondary Interventions
- (2013) Tyler J. VanderWeele et al. ANNALS OF INTERNAL MEDICINE
- High Blood Pressure: The Leading Global Burden of Disease Risk Factor and the Need for Worldwide Prevention Programs
- (2013) Samantha Bromfield et al. CURRENT HYPERTENSION REPORTS
- Strong rules for discarding predictors in lasso-type problems
- (2011) Robert Tibshirani et al. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY
- Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
- (2010) David M Kent et al. Trials
- General Cardiovascular Risk Profile for Use in Primary Care
- (2008) Ralph B. D’Agostino et al. CIRCULATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started